HopeStage
Back to all studies
RecruitingNCT07565428

Roluperidone for negative symptoms and relapse in schizophrenia

About this titleRead the official source — NCT07565428

This study evaluates the effectiveness of Roluperidone for people with schizophrenia.

Medication studyAges 18–55United States
The study in practice

Understand this study

What is this study about?

This study evaluates the effectiveness of Roluperidone for people with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Listed locations
Bellflower and 12 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 23, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
380
Sponsor
Minerva Neurosciences
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT07565428
Official title
Show the full official title

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Recruitment & locations

Currently recruiting

Bellflower · Culver City · Garden Grove

10 more locations
  • Riverside
  • Hallandale
  • Hollywood
  • Tampa
  • Atlanta
  • Decatur
  • Gaithersburg
  • Marlton
  • New York
  • Richardson

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the effectiveness of Roluperidone for people with schizophrenia.

Who is behind this study?

The study sponsor is Minerva Neurosciences.

Does this study involve medication?

Yes. The study involves medication, including Roluperidone, risperidone, aripiprazole, olanzapine and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies